These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20880169)

  • 1. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects.
    Kim HK; Park SH; Cheung DY; Cho YS; Kim JI; Kim SS; Chae HS; Kim JK; Chung IS
    J Gastroenterol Hepatol; 2010 Oct; 25(10):1618-25. PubMed ID: 20880169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 24-h recording of intragastric pH: technical aspects and clinical relevance.
    van Herwaarden MA; Samsom M; Smout AJ
    Scand J Gastroenterol Suppl; 1999; 230():9-16. PubMed ID: 10499456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies, dilemmas, and dialogues. Reduction of gastric acidity in the treatment of peptic ulcer disease: how low should we go?
    Peterson WL; Harford WV
    Am J Gastroenterol; 1991 Jun; 86(6):671-5. PubMed ID: 1674838
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
    Adachi K; Komazawa Y; Mihara T; Azumi T; Fujisawa T; Katsube T; Furuta K; Kinoshita Y
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1012-5. PubMed ID: 15955208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
    Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
    J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a conscious rat model for the discovery of novel agents that inhibit gastric acid secretion.
    Campbell CA; Gaskin PJ; Darton J; Chiu P; Lee K; McLean PG
    Eur J Pharmacol; 2008 Jul; 589(1-3):260-3. PubMed ID: 18571645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of gastric acid secretion and therapeutic results: is there any correlation?
    Corinaldesi R; Ghidini C; Ricci Maccarini M; Santaguida P; Fratesi E; Barbara G; Stanghellini V
    Ital J Gastroenterol; 1990; 22 Suppl 1():2-4. PubMed ID: 1983421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective.
    Orlando RC
    Am J Gastroenterol; 1996 Sep; 91(9):1692-6. PubMed ID: 8792683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The present state of knowledge on the treatment of peptic diseases with cimetidine].
    Romankiewicz JA; Reidenberg MM
    Internist (Berl); 1981 Dec; 22(12):762-6. PubMed ID: 6797984
    [No Abstract]   [Full Text] [Related]  

  • 11. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
    Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
    J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
    Beaumont H; Boeckxstaens GE
    Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Helicobacter pylori on gastritis, pentagastrin-stimulated gastric acid secretion, and meal-stimulated plasma gastrin release in the absence of peptic ulcer disease.
    Hurlimann S; Dür S; Schwab P; Varga L; Mazzucchelli L; Brand R; Halter F
    Am J Gastroenterol; 1998 Aug; 93(8):1277-85. PubMed ID: 9707051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinc salts provide a novel, prolonged and rapid inhibition of gastric acid secretion.
    Kirchhoff P; Socrates T; Sidani S; Duffy A; Breidthardt T; Grob C; Viehl CT; Beglinger C; Oertli D; Geibel JP
    Am J Gastroenterol; 2011 Jan; 106(1):62-70. PubMed ID: 20736941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian variations in gastric acid and pepsin secretion and intragastric bile acid in patients with reflux esophagitis and in healthy controls.
    Fiorucci S; Distrutti E; Di Matteo F; Brunori P; Santucci L; Mallozzi E; Bigazzi U; Morelli A
    Am J Gastroenterol; 1995 Feb; 90(2):270-6. PubMed ID: 7847299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of peptic ulcer and reflux esophagitis with enzyme inhibitors].
    Moriya S; Omura N; Kashiwagi H; Inagaki Y; Aoki T
    Nihon Rinsho; 1991 Sep; 49(9):2115-9. PubMed ID: 1835742
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of relapse of healed reflux esophagitis is related to the duration of intragastric pH > 4.
    Johnson DA; Katz PO; Levine D; Röhss K; Astrand M; Junghard O; Nagy P
    J Clin Gastroenterol; 2010 Aug; 44(7):475-8. PubMed ID: 20502348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
    Miner PB; Allgood LD; Grender JM
    Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.